Andrew Moreno

DocwireNews

Combining the selective glutaminase inhibitor telaglenastat with azacitidine is safe and effective for advanced myelodysplastic syndrome (MDS) management. This is according to findings from a single-arm, open-label, phase Ib/II study published in Nature Cancer.Lead author Courtney D DiNardo, MD, MSCE, of the University of Texas MD Anderson Cancer Center in Houston, wrote that the two agents formed &ldquo;a combined metabolic and epigenetic approach&rdquo; for advanced MDS. She noted &ldquo;[m]alignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation.&rdquo;The investigation involved a dose-escalation study with a cohort of six patients and a dose-expansion study with a cohort of 24 patients. Single-cell RNA sequencing was used to evaluate evidence of myeloid differentiation in patients who responded to the combination.The combination therapy was well tolerated by the study participants, who had an objective response rate of 70% and a median overall survival of 11.6 months. Complete remission within bone marrow occurred in 53% of participants.&ldquo;Glutamine transporter solute carrier family 38 member 1 in MDS stem cells was associated with clinical responses and predictive of worse prognosis in a large MDS cohort,&rdquo; Dr. DiNardo concluded.ReferenceDiNardo CD, Verma D, Baran N, et al. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024. doi:10.1038/s43018-024-00811-3

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Glutaminase Inhibition Plus Azacitidine Promising for Advanced MDS

A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.

Glutaminase Inhibition Plus Azacytidine Promising for Advanced MDS

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe